How were MyoKardia's earnings last quarter?

MyoKardia, Inc. (NASDAQ:MYOK) posted its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.44) by $0.16.

What other stocks do shareholders of MyoKardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MyoKardia investors own include NVIDIA (NVDA) , Micron Technology (MU) , Pfizer (PFE) , CVS Health (CVS) , Gilead Sciences (GILD) , AbbVie (ABBV) , Walt Disney (DIS) , Johnson & Johnson (JNJ) , Exelixis (EXEL) and RTX (RTX) .

NASDAQ:MYOK

MyoKardia (MYOK) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free MYOK Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $224.91
▼
$224.91
50-Day Range: $222.81
▼
$224.91
52-Week Range: $42.65
▼
$225.00

Volume: N/A
Average Volume: 752,969 shs
Market Capitalization: $11.99 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get MyoKardia alerts:

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About MyoKardia Stock (NASDAQ:MYOK)

MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

MYOK Stock News Headlines

April 11, 2024 | uk.investing.com

Astria Therapeutics expands board with new director

April 9, 2024 | finance.yahoo.com

Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 27, 2024 | seekingalpha.com

FULC Fulcrum Therapeutics, Inc.

March 16, 2024 | seekingalpha.com

Cytokinetics: CEO Talks Down Buyout Prospects

February 27, 2024 | uk.finance.yahoo.com

Q4 2023 Fulcrum Therapeutics Inc Earnings Call

February 27, 2024 | finance.yahoo.com

Fulcrum Therapeutics Inc (FULC) Reports Financial Results for Q4 and Full Year 2023

February 27, 2024 | markets.businessinsider.com

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

February 16, 2024 | cbsnews.com

If heart disease runs in your family, talk to your doctor about HCM

November 29, 2023 | finance.yahoo.com

Bristol Myers pours $100M into RNA drugs for cardiovascular diseases

November 29, 2023 | msn.com

Avidity and BMS enter $2.3bn deal for cardiovascular targets

November 28, 2023 | msn.com

Why Is RNA Therapeutics-Focused Avidity Biosciences Stock Trading Higher Today?

November 28, 2023 | msn.com

Avidity’s stock rockets on Bristol Myers deal that could mean $2.2 billion in milestone payments

November 22, 2023 | forbes.com

How Viz.ai Uses Artificial Intelligence To Treat Stroke Patients Faster

October 24, 2023 | benzinga.com

Why LianBio Stock Is Ripping Higher Today

October 24, 2023 | msn.com

Why Is LianBio (LIAN) Stock Up 130% Today?

October 24, 2023 | msn.com

Why LianBio Stock Is Skyrocketing Today

October 24, 2023 | finance.yahoo.com

LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets

October 9, 2023 | msn.com

Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B

October 4, 2023 | bizjournals.com

Peninsula biotech company looks to pump new life into heart disease treatments

August 31, 2023 | msn.com

Fulcrum Therapeutics (FULC) Price Target Increased by 30.97% to 10.78

July 27, 2023 | finance.yahoo.com

Cutera, Inc. Appoints Taylor Harris as Chief Executive Officer

July 27, 2023 | markets.businessinsider.com

Cutera Names Taylor Harris As CEO, Shares Gain

July 27, 2023 | marketwatch.com

Cutera Names Taylor Harris CEO, Ending Succession Tussle >CUTR

July 11, 2023 | finance.yahoo.com

Abivax Announces the Appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors

July 11, 2023 | markets.businessinsider.com

EQS-News: Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors

See More Headlines

Receive MYOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MyoKardia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/05/2020
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MYOK
CUSIP: N/A
CIK: 1552451
Web: www.myokardia.com
Phone: 650-741-0900
Fax: N/A
Employees: 318
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($4.38)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-276,210,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -47.99%
Return on Assets: -42.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 21.03
Quick Ratio: 21.03

Sales & Book Value

Annual Sales: $33.56 million
Price / Sales: 357.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.79 per share
Price / Book: 25.59

Miscellaneous

Outstanding Shares: 53,323,000
Free Float: N/A
Market Cap: $11.99 billion
Optionable: Optionable
Beta: 1.84

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Tassos Anastasios E. Gianakakos (Age 47)
Pres, CEO & Director
Comp: $987.02k
Mr. Taylor C. Harris (Age 44)
Chief Financial Officer
Comp: $604.47k
Dr. Robert S. McDowell (Age 62)
Chief Scientific Officer
Comp: $579.19k
Mr. Jake B. Bauer (Age 41)
Chief Bus. Officer
Comp: $547.2k
Mr. William C. Fairey Jr. (Age 54)
Chief Commercial Officer & Exec. VP
Comp: $905.02k
Dr. Leslie Leinwand
Co-Founder
Dr. Christine E. Seidman (Age 67)
Co-Founder
Dr. Jonathan G. Seidman
Co-Founder
Dr. James A. Spudich (Age 78)
Co-Founder
Michelle Corral
Exec. Director of Corp. Communications & Investor Relations

Key Competitors

View All Competitors

MYOK Stock Analysis - Frequently Asked Questions

How were MyoKardia's earnings last quarter?: MyoKardia, Inc. (NASDAQ:MYOK) posted its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.44) by $0.16.
What other stocks do shareholders of MyoKardia own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MyoKardia investors own include NVIDIA (NVDA), Micron Technology (MU), Pfizer (PFE), CVS Health (CVS), Gilead Sciences (GILD), AbbVie (ABBV), Walt Disney (DIS), Johnson & Johnson (JNJ), Exelixis (EXEL) and RTX (RTX).

This page (NASDAQ:MYOK) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MyoKardia (MYOK) Stock Price, News & Analysis

About MyoKardia Stock (NASDAQ:MYOK)

MYOK Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

MYOK Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info